Nurix Therapeutics Inc’s recently made public that its Chief Legal Officer Ring Christine unloaded Company’s shares for reported $0.13 million on Dec 02 ’24. In the deal valued at $21.73 per share,5,760 shares were sold. As a result of this transaction, Ring Christine now holds 28,084 shares worth roughly $0.54 million.
Then, CHRISTINE RING bought 5,760 shares, generating $127,354 in total proceeds.
Before that, Ring Christine sold 3,290 shares. Nurix Therapeutics Inc shares valued at $82,250 were divested by the Chief Legal Officer at a price of $25.00 per share. As a result of the transaction, Ring Christine now holds 28,084 shares, worth roughly $0.54 million.
BTIG Research initiated its Nurix Therapeutics Inc [NRIX] rating to a Buy in a research note published on December 10, 2024; the price target was $35. A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who began to cover the stock in early December with a ‘”an Outperform”‘ rating. UBS began covering NRIX with “Buy” recommendation on October 24, 2024. Jefferies started covering the stock on October 11, 2024. It rated NRIX as “a Buy”.
Price Performance Review of NRIX
On Friday, Nurix Therapeutics Inc [NASDAQ:NRIX] saw its stock fall -4.11% to $19.11. Over the last five days, the stock has lost -4.64%. Nurix Therapeutics Inc shares have risen nearly 85.17% since the year began. Nevertheless, the stocks have risen 96.00% over the past one year. While a 52-week high of $29.56 was reached on 11/11/24, a 52-week low of $7.65 was recorded on 01/29/24. SMA at 50 days reached $23.09, while 200 days put it at $20.04.
Levels Of Support And Resistance For NRIX Stock
The 24-hour chart illustrates a support level at 18.61, which if violated will result in even more drops to 18.10. On the upside, there is a resistance level at 19.92. A further resistance level may holdings at 20.72. The Relative Strength Index (RSI) on the 14-day chart is 36.30, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.86, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.05%. Stochastics %K at 13.44% indicates the stock is a buying.
How much short interest is there in Nurix Therapeutics Inc?
A steep rise in short interest was recorded in Nurix Therapeutics Inc stocks on 2024-12-13, growing by 0.23 million shares to a total of 9.83 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 9.6 million shares. There was a rise of 2.31%, which implies that there is a positive sentiment for the stock.
